Biosimilars
TL 011
05-25-2010 |
20:57 hs.
Teva Pharmaceutical Industries Ltd. Announced the initiation of testing for a generic version of Roche Holding AG blockbuster biologic drug Rituxan/MabThera (Rituximab),indicated to treat rheumatoid arthritis.
12-23-2008 |
12:14 hs.
10-07-2008 |
13:53 hs.
10-06-2008 |
11:23 hs.
09-16-2008 |
11:34 hs.
Teva announced that the EMEA granted a Marketing Authorization for its human granulocyte colony stimulating factor (G-CSF) product, TevaGrastim, a generic form of Amgen’s Neupogen.
09-04-2008 |
13:02 hs.
First U.S. human bioequivalence data
07-10-2008 |
16:36 hs.
Insmed Inc. a developer of follow-on biologics and biopharmaceuticals, announced it has demonstrated the bioequivalence of INS-19, the company’s recombinant human granulocyte colony stimulating factor (G-CSF), compared with AMGEN´s Neupogen, an FDA-approved G-CSF product for the treatment of neutropenia. The product is in Phase II clinical trials. Further details.
Neutropenia
02-22-2008 |
10:20 hs.
London-based watchdog recommends approval of 4 biosimilar version of Amgen’s best-selling Neupogen to treat low white blood cell counts
